We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients (CIN-RG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01456013
Recruitment Status : Unknown
Verified December 2018 by CardioRenal Systems, Inc..
Recruitment status was:  Active, not recruiting
First Posted : October 20, 2011
Last Update Posted : December 12, 2018
Information provided by (Responsible Party):
CardioRenal Systems, Inc.

Brief Summary:
Contrast-Induced Nephropathy (CIN) can occur when patients with pre-existing kidney problems undergo procedures that use iodinated contrast media, such as cardiac catheterizations. RenalGuard Therapy was developed to enable the patient to clear the contrast out of their kidney before it can do significant damage. This study aims to enroll patients with increased risk of developing CIN who are scheduled for a cardiovascular catheterization. Patients will be randomized to either RenalGuard therapy or standard therapy.

Condition or disease Intervention/treatment Phase
Contrast Induced Nephropathy Device: RenalGuard Therapy Drug: Standard Therapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 326 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory
Study Start Date : January 2012
Actual Primary Completion Date : March 2018
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Active Comparator: Standard Therapy
Standard of care for patients at risk of CIN
Drug: Standard Therapy
Standard of care for patients at risk of CIN

Experimental: RenalGuard Therapy
Induced Diuresis with Matched Replacement
Device: RenalGuard Therapy
Induced Diuresis with matched replacement

Primary Outcome Measures :
  1. Incidence of Contrast Induced Nephropathy [ Time Frame: 72 hours ]

Secondary Outcome Measures :
  1. Major Adverse Cardiac Events [ Time Frame: 90 days ]
  2. Mean peak increase in serum creatinine post contrast administration [ Time Frame: 72 hours ]
  3. Proportion of patients who develop CIN at 7 days post contrast administration [ Time Frame: 7 days ]
  4. Proportion of patients who maintain a rise in serum creatinine at 7 days [ Time Frame: 7 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or non-pregnant female equal or greater than the age of 18 years old and is able to provide informed consent.
  • Subject is scheduled to undergo an elective catheterization procedure
  • Hemodynamically stable
  • At increased risk of developing CIN
  • Subject has agreed to all follow-up testing.

Exclusion Criteria:

  • Class 4 Congestive Heart Failure (CHF)or a documented left ventricular ejection fraction < 30%
  • Is anuric or has undergone renal replacement therapy within the past month, or has a known inability to have a Foley catheter placed.
  • Subject has been hospitalized or treated medically for any change in renal function over the past week (i.e. dialysis, etc.), or a significant change in renal function is noted at time of screening.
  • Has documented severe Aortic Stenosis.(Note: Subjects who have undergone successful replacement or repair of their aortic valve are not excluded.)
  • Currently has a known clinically significant electrolyte imbalance or clinically significant arrhythmias which compromise subject's hemodynamic state.
  • Patient has severe anemia (hemoglobin < 8.0 g/dL) at screening
  • Has received contrast within 10 days of procedure or has a planned additional cardiac or renal or other major surgical procedure within the 7 day follow-up period.
  • Has ruled in for a Serious Heart Attack within 48 hours of the planned procedure
  • Has documented respiratory insufficiency as evidenced by an oxygen saturation of < 90% on room air assessed on day of procedure.
  • Planned addition, discontinuation or dose adjustment of nephrotoxic drugs
  • Subject has a known hypersensitivity to furosemide and/or the contrast agent being used.
  • Subject is currently, plans, or has been enrolled in another clinical study involving use of an investigational drug or device within the prior 30 days.
  • Subject is pregnant or breastfeeding.
  • Subject is unable to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01456013

Show Show 30 study locations
Sponsors and Collaborators
CardioRenal Systems, Inc.
Layout table for investigator information
Principal Investigator: Charles Davidson, MD Northwestern University
Principal Investigator: Richard Solomon, MD University of Vermont
Principal Investigator: Roxana Mehran, MD Icahn School of Medicine at Mount Sinai
Layout table for additonal information
Responsible Party: CardioRenal Systems, Inc.
ClinicalTrials.gov Identifier: NCT01456013    
Other Study ID Numbers: RGS001D
First Posted: October 20, 2011    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases